Vamorolone
Becker Muscular Dystrophy (BMD)
Clinical TestingActive
Key Facts
Indication
Becker Muscular Dystrophy (BMD)
Phase
Clinical Testing
Status
Active
Company
About ReveraGen BioPharma
ReveraGen BioPharma is a pioneering biotech that has successfully developed and gained regulatory approval for vamorolone, a first-in-class dissociative steroid for Duchenne muscular dystrophy. The company achieved this milestone through an innovative venture philanthropy and public-private partnership model, operating with an exceptionally lean team. Its focus remains on leveraging its steroid chemistry expertise to create safer anti-inflammatory treatments for rare diseases with high unmet need.
View full company profileTherapeutic Areas
Other Becker Muscular Dystrophy (BMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Myomatrix Stabilization Program | Strykagen | Preclinical |
| EDG-5506 | Edgewise Therapeutics | Phase 2/3 |